Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Anti CD19 CAR T cell therapeutic Beijing Doing Biomedical (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Beijing Doing Biomedical
- 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
- 14 Dec 2021 Results (n=64 ) from NCT03173417, NCT02546739, NCT03312205 and NCT03671460; analysing factors associated with efficacy following CD19 CAR-T therapy among B-ALL patients with TP53 mutation/chromosome 17p deletion, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 23 Jan 2021 Planned End Date changed from 1 Sep 2020 to 1 Mar 2023.